How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?

AbbVie's Q2 2025 oncology sales are estimated to decline 2% year-over-year to $1.6 billion, as the continued decrease in Imbruvica sales is expected to outweigh growth from newer drugs like Venclexta, Epkinly, Elahere, and modest contributions from recently approved Emrelis. For the July 31st earnings report, investor focus will primarily be on the performance of the company's flagship immunology franchise, despite the oncology portfolio expansion. ABBV shares have outperformed the industry year-to-date, trading at 14.21x forward earnings, which is below the industry average but above its five-year mean, presenting a mixed valuation picture.

Analysis

AbbVie's oncology segment is facing a near-term contraction, with model estimates projecting a 2% year-over-year revenue decline to $1.6 billion for Q2 2025. This downturn is primarily attributed to the persistent sales erosion of its older blood-cancer drug, Imbruvica, which is succumbing to heightened competition from novel oral therapies. The negative impact from Imbruvica is expected to more than offset growth from newer assets like Venclexta, Epkinly, and Elahere, while the recently approved lung cancer treatment, Emrelis, is anticipated to make only a modest initial contribution. Despite strategic expansion, AbbVie's oncology business, at 12% of first-quarter revenue, remains a significantly smaller part of its portfolio compared to peers like AstraZeneca, where oncology constitutes 41% of sales. Consequently, investor focus for the July 31 earnings report will be less on the oncology results and more on the performance of the critical immunology franchise, particularly the sequential growth and market share gains of Rinvoq and Skyrizi. The company's valuation presents a mixed picture; while shares have outperformed the industry year-to-date, the forward P/E of 14.21x sits below the industry average but above its own five-year mean, a situation clouded by a recent downward revision in 2025 EPS estimates.

Key Decisions for Investors

• Investors should prioritize the performance of the immunology franchise, specifically the growth rates of Rinvoq and Skyrizi, in the upcoming Q2 report, as this segment is the primary driver of AbbVie's value proposition, not the currently challenged oncology unit.
• Monitor the rate of Imbruvica's sales decline closely, as a steeper-than-expected fall could indicate intensifying competitive pressures and signal a greater headwind to overall growth.
• Given the mixed valuation and recent downward revision to 2025 EPS estimates, consider whether the stock's year-to-date outperformance fully prices in the near-term oncology weakness against the long-term immunology growth story.
• Use the robust oncology growth reported by competitors like AstraZeneca (+13%) and Pfizer (+7%) as a benchmark to assess the relative underperformance of AbbVie's oncology segment and its long-term competitive positioning.